DOCSLIB.ORG

COVID-19 Vaccines BJC and WUSM Employees

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
COVID-19 Vaccines BJC and WUSM Employees COVID-19 vaccines BJC and WUSM employees FAQs – updated September 10, 2021 Updates to this document have been made in red. The content in this document is intended for BJC/Washington University School of Medicine (WUSM) employees only, not for the general public. Click the topic below to go directly to the section: • Vaccine requirement and distribution – BJC/WUSM employees and contingent workers • Vaccine safety • Vaccine effectiveness • Vaccine distribution - public • Questions prior to receiving the vaccine • After I get the vaccine • More about the vaccines Vaccine requirement and distribution – BJC/WUSM employees and contingent workers 1. Which vaccine was officially approved by the FDA, and how is this different than the emergency use authorization the FDA granted the vaccine previously? On August 23, 2021, the Pfizer COVID-19 vaccine officially received full FDA approval. It is the first COVID-19 vaccine to receive this approval. This action by the FDA may influence some unvaccinated citizens to get vaccinated, as it is additional validation that the vaccine is safe and effective in preventing severe COVID-19 infection. For BJC, the FDA action does not change our requirement that all team members be vaccinated. 2. What is the deadline for employees to be vaccinated? September 15 is now the deadline for receiving a dose of any COVID-19 vaccine: first doses of a two-dose series or the single-dose Johnson & Johnson/Janssen vaccine. At this point, employees with a single dose of a two-dose vaccine will be “conditionally compliant” with the expectation 1 COVID-19 vaccine rollout to BJC and WUSM employees FAQs CS_586771 6/24/21 that they complete the series within 30 days. If vaccination is obtained outside of BJC Occupational Health, team members are required to provide documentation for the first AND second dose to Occupational Health. Email documentation to [email protected]. 3. Why did BJC extend the September 15 deadline for the vaccine? Actually, the September 15 vaccination deadline remains in place. A number of our employees expressed uneasiness about receiving a vaccine without FDA approval. With the August 23 FDA approval of the Pfizer COVID-19 vaccine, we felt it would be reasonable and appropriate to provide time for anyone who was waiting for full approval before starting the vaccine series. September 15 is now the deadline for receiving a dose of any COVID-19 vaccine: first doses of a two-dose series or the single-dose Johnson & Johnson/Janssen vaccine. At this point, employees with a single dose of a two-dose vaccine will be “conditionally compliant” with the expectation that they complete the series within 30 days. This recent update to the timeline reflects our firm belief that employees who were reluctant to get the vaccine while under Emergency Use Authorization (EU) status will now do so without having to be suspended. 4. Will I be considered fully compliant on September 15 if I have received one dose of a two-series COVID-19 vaccine? No, an employee is fully compliant only after successfully obtaining the full series of the one- dose J&J or both doses of a two-dose series vaccine. 5. If I get my first dose by September 15 will I still get the 8-hour PTO deposit? To receive the extra 8 hours of PTO (or payout, if you are at the max), you must be fully vaccinated by 5:00 p.m. on September 15, as originally communicated. This means you will need to have completed both doses of a two-dose series or the single Johnson & Johnson/Janssen dose. 6. If I receive the first dose of my two-dose COVID-19 vaccine series on or before September 15, will I be suspended on September 15? No, employees will not be suspended if they have received a first dose (or single Johnson&Johnson/Janssen dose) by September 15 at 5:00 p.m. Employees receiving Pfizer or Moderna must successfully complete both doses of their vaccine series by October 15, 2021, to achieve full compliance. Failure to do so will subject the employee to suspension until they become compliant (up to 30 days). Failure to become compliant within the 30-day suspension period will result in termination. 7. What is the deadline for obtaining the second dose of a two-dose vaccine? If the employee has obtained their first dose on or before September 15, the employee must obtain their second dose according to the manufacturer’s recommendation, and no later than October 15. If the employee fails to obtain their first vaccine by September 15, the employee will be suspended without pay for up to 30 days. Employees will be allowed to return to work after completing the vaccine series (single J&J or two-dose series of Pfizer or Moderna) making them fully vaccinated. If they do not complete their series within the recommended interval, they will be terminated. 2 COVID-19 vaccine rollout to BJC and WUSM employees FAQs CS_586771 6/24/21 8. Will I be allowed to return to work after obtaining my first dose of either Pfizer or Moderna? No, employees who have been suspended will be allowed to return to work after completing the vaccine series (single Johnson&Johnson/Janssen or two-dose series of Pfizer or Moderna) making them fully vaccinated. If they do not complete their series within the recommended interval, they will be terminated. 9. With all our staffing challenges, how can we suspend or terminate people who are not willing to obtain this vaccine? It is our obligation and commitment to do whatever we can to promote and maintain a safe environment for our patients, visitors, and one another. Our decision to make the COVID-19 vaccine mandatory is, in part, to help us overcome many of the impacts that COVID-19 is having on our employee population. The decision to get the vaccine is personal. But it is a requirement of working at BJC HealthCare. 10. Will I be required to complete mandatory testing? Initially, employees working in Illinois who have not been fully vaccinated or who have an approved exemption (medical or religious) will be required to start weekly testing on September 19 unless they are 100% alternative work site (AWS). Any AWS employee who has received an approved exemption and plans to come on site will need to be tested prior to coming in – even if only coming in for one day. In the future, all AWS employees with an approved exemption may be required to complete mandatory testing. 11. When do these testing requirements go into effect? The testing requirement will begin in Illinois the week starting September 19. If you are scheduled to work the week of September 19, you must receive your first test before September 26 and be tested every week you are scheduled thereafter. The state of Missouri does not currently require testing, but BJC is evaluating its guidelines and will release more information soon on plans to test team members at Missouri facilities. 12. Who do these testing requirements apply to? Employees at Illinois facilities who are not fully vaccinated or who have an approved exemption (medical or religious) from receiving the COVID-19 vaccine will be required to complete mandatory weekly surveillance testing unless they are 100% alternative work site (AWS). To be fully vaccinated, you must be at least two full weeks past receiving either the second dose of a two-dose Pfizer or Moderna vaccine, or the single dose Johnson & Johnson vaccine. 13. Does this apply to AWS workers? Team members with vaccine exemptions who are 100% AWS do not need the weekly tests. However, any AWS employee who is not fully vaccinated or who has received an approved exemption and splits their time between AWS and in-person, or plans to come on site for any duration will need to be tested prior (within 72 hours) to coming in. 14. Where can team members receive their weekly tests? These are BJC’s Illinois testing locations: 3 COVID-19 vaccine rollout to BJC and WUSM employees FAQs CS_586771 6/24/21 Alton Multi Specialists – 8 a.m.-4:30 p.m. – M-F Bethalto Convenient Care – 8 a.m.-8 p.m. – Daily Godfrey Convenient Care – 8 a.m.-8 p.m. – Daily Swansea Collection Site – 8 a.m.-4:30 p.m. – M-F and 8 a.m.-12:30 p.m. – Sat/Sun *Alton Memorial Hospital team members may also be tested at AMH Occupational Health. 15. What type of COVID test do I have to take? Employees will be administered the PCR nasal test. 16. What if I don’t want a PCR nasal test? Can I get an alternate test? BJC is providing the PCR nasal test at no cost to unvaccinated employees with an approved exemption. This test is the most accurate and reliable. This is the test that is available at the designated collection sites noted above. 17. How often do I need to be tested? BJC employees with scheduled shifts every week will require testing every week. PRNs, AWS team members and anyone else not scheduled every week will be expected to receive a test within 72 hours prior to their first on-site shift per week. 18. Can I get tested during my scheduled work hours? Yes, most employees are able to be tested during work hours. This will depend on your work schedule, collection site hours, and your department needs, and will vary by HSO. Please check with your manager. 19. Will I be reimbursed for my time if I am tested on non-work hours? If you are an hourly employee and testing is not available during your regular work hours, you will be compensated for one hour if you get your mandated surveillance COVID test before or after your scheduled shift or if you go for testing on your day off.
Load more

Recommended publications
  • COVID-19 Vaccination Programme: Information for Healthcare Practitioners
    COVID-19 vaccination programme Information for healthcare practitioners Republished 6 August 2021 Version 3.10 1 COVID-19 vaccination programme: Information for healthcare practitioners Document information This document was originally published provisionally, ahead of authorisation of any COVID-19 vaccine in the UK, to provide information to those involved in the COVID-19 national vaccination programme before it began in December 2020. Following authorisation for temporary supply by the UK Department of Health and Social Care and the Medicines and Healthcare products Regulatory Agency being given to the COVID-19 Vaccine Pfizer BioNTech on 2 December 2020, the COVID-19 Vaccine AstraZeneca on 30 December 2020 and the COVID-19 Vaccine Moderna on 8 January 2021, this document has been updated to provide specific information about the storage and preparation of these vaccines. Information about any other COVID-19 vaccines which are given regulatory approval will be added when this occurs. The information in this document was correct at time of publication. As COVID-19 is an evolving disease, much is still being learned about both the disease and the vaccines which have been developed to prevent it. For this reason, some information may change. Updates will be made to this document as new information becomes available. Please use the online version to ensure you are accessing the latest version. 2 COVID-19 vaccination programme: Information for healthcare practitioners Document revision information Version Details Date number 1.0 Document created 27 November 2020 2.0 Vaccine specific information about the COVID-19 mRNA 4 Vaccine BNT162b2 (Pfizer BioNTech) added December 2020 2.1 1.
    [Show full text]
  • Monday, September 14, 2020 Home-Delivered $1.90, Retail $2.20 Tears Flow
    Nupepa o Te Tairawhiti THE GISBORNE HERALD RĀHINA, MAHURU 9, 2019 I MONDAY, SEPTEMBER 9, 2019 HOME-DELIVERED $1.70, RETAIL $2.00 TE NUPEPA O TE TAIRAWHITI RAHINA, MAHURU 14, 2020 I MONDAY, SEPTEMBER 14, 2020 HOME-DELIVERED $1.90, RETAIL $2.20 TEARS FLOW AT C COMPANY HOUSE PAGE 3 PUKANA: Kereru class students at Te TOLAGA BAY CIVIL DEFENCE PAGE 4 ‘All day, every day, te reo is our way’ Hapara School practise their te reo Maori every day. Te Wiki o te reo Maori VOLUNTEERS RECOGNISED is another week where the students UNHEARDOFSAVINGS! IT is Te Wiki o te reo Maori Ms Neilson said. what they teach us every embrace te ao Maori. The children are (Maori Language Week) but “Singing connects us morning so we will become pictured with teacher Tanya Neilson. te reo Maori is used at Te and brings us together better performers, therefore Picture by Liam Clayton. Hapara School every school and creates memories and incorporating the intrinsic day. memory space in our brains. link to culture and identity PAGES Each day the kereru “We know our students and the essential element 5-8,11, whanau class have the enjoy our morning sessions of whanaungatanga (the 12, 13, 16 same routine of performing and they could independently importance of people and a waiata (song), karakia run it on their own. connectedness),” said Ms (prayer) and haka and “We are a culturally diverse Neilson. HEARING• Mask refusal halts Fullers ferry trip practise use of te reo Maori whanau and celebrate and “The school’s focus this •NEW Political party leader’s Covid theories kupu (words) and commands respect all people.” year has been about creating raising fears for Maori health because that is a part of who Te Hapara has two kapa a sense of belonging and PBL they are as a class, says haka tutors — Papa Pura and we feel that through culture, • Expecting ugly GDP figures for quarter teacher Tanya Neilson.
    [Show full text]
  • Safe Return Plan FINAL
    Safe Return to In-Person Instruction and Continuity of Service Pursuant to the Federal American Rescue Plan Act Hazlet Township School District June 2021 Revision: August 2021 HAZLET TOWNSHIP PUBLIC SCHOOLS ADMINISTRATION 2021-2022 BOARD OF EDUCATION Board President Victor J. Iannello, Jr. Vice President Jodie Moreno Board Members David Asfour Edward Barrett John Granite Steven Grossman William Kolibas Laura O’Hara George Theis Student Member James Grebenstein CENTRAL OFFICE ADMINISTRATION Superintendent of Schools Scott Ridley, Ed.D. Assistant Superintendent of Schools Joseph J. Annibale School Business Administrator/Board Secretary Christopher J. Mullins DIRECTORS Director of Curriculum, Instruction & Testing Heather Schwarz Director of Special Services Jacqueline Hafner Director of School Counseling Services Julie Ciccarone Director of Athletics John DeGenito SUPERVISORS Supervisor of Language Arts Suzanne Capraro Supervisor of Mathematics Jennifer Martins Supervisor of Science Michael Miller Supervisor of Special Services Chantal Molino Supervisor of Buildings & Grounds Charles Hildner Network Administrator Joseph Emerson District Affirmative Action Officer Andrew Piotrowski, Ed.D. Title IX Coordinator Suzanne Capraro BUILDING PRINCIPALS Sycamore Drive ECLC Gina Dorozynski Lillian Drive School Kathleen Matsutani Middle Road School Katherine Egan Raritan Valley School John Verderosa Beers Street School Ian Collis Cove Road School Dara Van Pelt Hazlet Middle School Christine McCoid, Ed.D. Raritan High School Andrew Piotrowski, Ed.D. Hazlet Township School District Date: June 15, 2021 Revised: August, 2021 1. Maintaining Health and Safety For each mitigation strategy listed below (A–H), please describe how the LEA will maintain the health and safety of students, educators, and other staff and the extent to which it has adopted policies, and a description of any such policies, on each of the following safety recommendations established by the CDC.
    [Show full text]
  • Negative Attitudes About Facemasks During the COVID-19 Pandemic
    medRxiv preprint doi: https://doi.org/10.1101/2020.11.17.20233585; this version posted November 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. 1 1 2 Running head: Negative attitudes about facemasks 3 4 5 Negative attitudes about facemasks during the COVID-19 pandemic: The dual importance of 6 perceived ineffectiveness and psychological reactance 7 Steven Taylor1 and Gordon J. G. Asmundson2 8 1Department of Psychiatry, University of British Columbia, Vancouver, BC, CANADA 9 2Department of Psychology, University of Regina, Regina, SK, CANADA 10 11 12 Correspondence: Steven Taylor, PhD, Department of Psychiatry, University of British Columbia, 13 Vancouver, Canada, V6E 2A1. E-mail: [email protected]. 14 15 Acknowledgements: The authors thank Michelle M. Paluszek, Caeleigh A. Landry, and Geoffrey 16 S. Rachor for their assistance in completing this study. 17 18 19 20 21 22 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.11.17.20233585; this version posted November 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. 2 23 Abstract 24 This study reports a comprehensive empirical investigation of the nature and correlates of anti- 25 mask attitudes during the COVID-19 pandemic.
    [Show full text]
  • The Political Economy of Covid-19 Vaccines
    TIF - The Political Economy of Covid-19 Vaccines JAYATI GHOSH March 5, 2021 Elderly waiting in line for their shots at a mass vaccination drive at Ecatepec town of Mexico (22 February) | Jose M. Ruiz/Eyepix/abacapress.com Vaccine grabs, the refusal to relax patents to enable mass production, and the use of vaccines for diplomacy run the risk that poorer nations may not be protected against Covid-19 quickly enough. This will prolong the pandemic, even for the richer nations. The Covid-19 pandemic has been unusual in several ways: the disproportionate extent to which people in rich countries (particularly in Europe and North America) have been affected; the sheer scale of the policy response for containment; and the speed and urgency of the global response. The active interest in controlling the pandemic in rich countries shaped individual national responses as well as global policy. There was a massive push for vaccine development, through large subsidies for research and development to drug companies, pre-orders of vaccines, and other support by the US, Russia, China, and European countries. Page 1 www.TheIndiaForum.in March 5, 2021 The production and distribution of Covid-19 vaccines has exposed and intensified global inequality. This led to the rapid development of multiple Covid-19 vaccine candidates and even more rapid regulatory approval to several of them. Typically, vaccines take several years to be developed and approved, partly because of extended clinical trials to check for all possible responses. But some Covid-19 vaccine candidates were given official approval in Russia and China even before the essential Phase III trials were completed.
    [Show full text]
  • IN the SUPREME COURT of INDIA CIVIL ORIGINAL JURISDICTION Suo Motu Writ Petition (Civil) No.3 of 2021 in RE: DISTRIBUTION of ES
    Reportable IN THE SUPREME COURT OF INDIA CIVIL ORIGINAL JURISDICTION Suo Motu Writ Petition (Civil) No.3 of 2021 IN RE: DISTRIBUTION OF ESSENTIAL SUPPLIES AND SERVICES DURING PANDEMIC. 1 O R D E R This order has been divided into the following sections to facilitate analysis: A Introduction B Outline of the Disaster Management Act C Medical Infrastructure C.1 Submissions in UOI’s Affidavits C.2 National Policy for Admission in Hospitals D Oxygen allocation and availability E Vaccines E.1 Vaccine capacity and disbursal E.2 Vaccine pricing F Potentiality of Compulsory Licensing for vaccines and essential drugs G Supply of Essential Drugs G.1 Submissions in the Central Government’s Affidavits G.2 Recommendations G.3 Black Marketing H Recommendations for augmenting healthcare workforce I Epilogue J Conclusion 2 PART A A Introduction 1 The genesis of this suo motu writ petition is in an order dated 22 April 2021. This Court took note of the unprecedented humanitarian crisis in the country, following the outbreak of the COVID-19 pandemic. Notices were issued to the Union of India1, the Governments of the States and Union Territories2, and to several petitioners who were before the High Courts. The Court observed: “the Union Government, the State Governments/Union Territories and the parties, who appeared to have approached the High Courts to show cause why uniform orders be not passed by this Court in relation to a) Supply of oxygen; b) Supply of essential drugs; c) Method and manner of vaccination; and d) Declaration of lockdown” The Court directed the Central Government to : “1.
    [Show full text]
  • COVID-19 Vaccines: Frequently Asked Questions
    COVID-19 vaccines: Frequently asked questions The following information concerns the storage, handling and use of COVID-19 vaccines from the following manufacturers: • Moderna • Pfizer/BioNTech • University of Oxford/AstraZeneca These vaccines have been included because they have received emergency use authorisations/ approvals and phase III clinical trial data are available about their safety and efficacy. This document was published on 28 January 2021. As other COVID-19 vaccines become widely used, receive national approvals and possess phase III clinical trial data, they will be added to this document. 1. How do the different vaccines work, i.e., mRNA vaccines vs viral-vector? Category Developer Mechanism Nucleic acid Moderna A person receives genetic material — mRNA — that vaccines Pfizer/BioNTech encodes the viral protein. When these genetic (proteins that instructions are injected the muscle cells translate them direct to make the viral protein directly in the body. This gives production of the immune system a preview of what the real virus other proteins): looks like without causing disease. This preview gives mRNA or DNA the immune system time to design powerful antibodies that can neutralise the real virus if the individual is ever infected. For information about how mRNA vaccines work see: https://theconversation.com/how-mrna-vaccines-from- pfizer-and-moderna-work-why-theyre-a-breakthrough- and-why-they-need-to-be-kept-so-cold-150238 https://www.cdc.gov/vaccines/covid-19/hcp/mrna- vaccine-basics.html Further information on safety and efficacy: Polack FP, Thomas SJ, Kitchin N, et al, for the C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine.
    [Show full text]
  • Assessing the Level and Determinants of COVID-19 Vaccine Confidence In
    medRxiv preprint doi: https://doi.org/10.1101/2021.06.11.21258775; this version posted June 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Assessing the level and determinants of COVID-19 Vaccine Confidence in Kenya Stacey Orangi 1,2*, Jessie Pinchoff3, Daniel Mwanga4, Timothy Abuya4, Mainga Hamaluba5,6, George Warimwe5,6, Karen Austrian4, Edwine Barasa1,6 Authors’ affiliation 1 Health Economics Research Unit (HERU), KEMRI-Wellcome Trust Research Program, Nairobi, Kenya 2 Institute of Healthcare Management, Strathmore University, Nairobi, Kenya 3 Population Council, New York, USA 4 Population Council, Nairobi, Kenya 5 KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya 6 Nuffield Department of Medicine, Oxford University, UK *Corresponding author: [email protected] ABSTRACT The government of Kenya has launched a phased rollout of COVID-19 vaccination. A major barrier is vaccine hesitancy; the refusal or delay of accepting vaccination. This study evaluated the level and determinants of vaccine hesitancy in Kenya. We conducted a cross-sectional study administered through a phone-based survey in February 2021 in four counties of Kenya. Multivariate logistic regression was used to identify individual perceived risks and influences, context-specific factors, and vaccine-specific issues associated with COVID-19 vaccine hesitancy. COVID-19 vaccine hesitancy in Kenya was high: 60.1%. Factors associated with vaccine hesitancy included: older age, lower education level, perceived difficulty in adhering to government regulations on COVID-19 prevention, less adherence to wearing of face masks, not having ever been tested for COVID-19, no reported socio- economic loss as a result of COVID public-health restriction measures, and concerns regarding vaccine safety and effectiveness.
    [Show full text]
  • Efforts at COVID-19 Vaccine Development
    Review Efforts at COVID-19 Vaccine Development: Challenges and Successes Azizul Haque 1,* and Anudeep B. Pant 2 1 One Medical Center Drive, Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Lebanon, NH 03756, USA 2 New Orleans East Hospital, 5620 Read Blvd, New Orleans, LA 70127, USA; [email protected] * Correspondence: [email protected] Received: 23 November 2020; Accepted: 3 December 2020; Published: 6 December 2020 Abstract: The rapid spread of SARS-CoV-2, the new coronavirus (CoV), throughout the globe poses a daunting public health emergency. Different preventive efforts have been undertaken in response to this global health predicament; amongst them, vaccine development is at the forefront. Several sophisticated designs have been applied to create a vaccine against SARS-CoV-2, and 44 candidates have already entered clinical trials. At present, it is unclear which ones will meet the objectives of efficiency and safety, though several vaccines are gearing up to obtain emergency approval in the U.S. and Europe. This manuscript discusses the advantages and disadvantages of various vaccine platforms and evaluates the safety and efficacy of vaccines in advance stages. Once a vaccine is developed, the next challenge will be acquisition, deployment, and uptake. The present manuscript describes these challenges in detail and proposes solutions to the vast array of translational challenges. It is evident from the epidemiology of SARS-CoV-2 that the virus will remain a threat to everybody as long as the virus is still circulating in a few. We need affordable vaccines that are produced in sufficient quantity for use in every corner of the world.
    [Show full text]
  • Face Covering Obstinacy: Ideology Unmasked
    Open Access Journal of Community Medicine & Health Care Mini Review Face Covering Obstinacy: Ideology Unmasked DeBoy JL* and Monsilovich SB Department of Health Sciences, Lincoln University, New Abstract Zealand Despite myriad public health guidelines strongly encouraging use of face *Corresponding author: James L DeBoy, Department coverings and select government entities requiring face mask use during the of Health Sciences, Lincoln University, New Zealand COVID-19 viral pandemic, many Americans vehemently protest and resist the community call for compliance. While the current social-political climate Received: October 13, 2020; Accepted: November 03, of perceived government overreach plays a major role in mask refusal, there 2020; Published: November 10, 2020 are other factors. This paper will explore those motivations that undergird this dangerous behavior that threatens not just the welfare of the non-user but also the health of the larger community. Keywords: COVID-19; Face masks; Public health guidelines Introduction conflicting public health edicts caused a number of local public health officials to ignore the CDC agency and follow their own judgments In the past seven months much has been written about the (Vestal & Ollove, 2020). An unfortunate result of eroding trust in COVID-19 pandemic and its debilitating effect upon the nation’s the CDC confuses and possibly leads the general public to disregard health and economic statuses. While the entire world awaits guidance that could save lives. the arrival of an effective vaccine, the three most widely-touted proactive measures designed to contain the virus’ spread consist of The published data on COVID-19’s morbidity and mortality rates sheltering in-place, social distancing, and wearing of face coverings.
    [Show full text]
  • Covid-19 Under Democracy and Autocracy
    © Rutgers, The State University of New Jersey (New Brunswick) This publication is the work of the Spring 2021 Capstone class of the United Nations and Global Policy Studies Master of Arts program (UNMA), Political Science Department, Rutgers University (New Brunswick) June 2021 Application for permission to reproduce or translate all or any part of this publication should be made to: UNMA Secretariat Hickman Hall 89 George Street New Brunswick, NJ 08901 Email: [email protected] Title: Covid-19 Under Democracy and Autocracy Editor: Dr. Roland Rich Cover Design: Ian DeFalco Layout: Camilla Bober ISBN 978-0-578-92527-1 CONTENTS Contributors 1 Chapter 1 A Project is Born 4 Roland Rich Chapter 2 Australia’s Covid-19 Response: 10 The Achilles Heel Shahinaz Abdelhamid Chapter 3 Brazil: Negligence and Populism during 34 a Global Health Crisis Gabriela Casco Chapter 4 Cuba’s Vaunted Medical System Faces Covid-19 54 Javier Nino Chapter 5 Federalism, the EU, and Human Rights 68 in Germany under COVID-19 Camilla Bober Chapter 6 Russia: A Contest between Science and Denial 94 Amar Wason Chapter 7 South Africa Faces Covid-19 116 Delaney Charydczak Chapter 8 Taiwan: A Near Perfect Response 128 to the Coronavirus Pandemic Ryan Prieto Chapter 9 The Impact of Covid-19 on Elections 148 in Uganda Susan Ombwayo Chapter 10 The United Kingdom: Covid-19 162 and the Decay of Democracy Arsanious Hanna Chapter 11 Vietnam: Looking beyond Regime Type 182 Daphnée A.M. Fleurant Chapter 12 Conclusions, Constatations and Concerns 196 Roland Rich Bibliography 224 1 CONTRIBUTORS Shahinaz Abdelhamid received her B.S.
    [Show full text]
  • Glove and Other PPE Guidance for COVID-19 Vaccine Administration
    Updated January 27, 2021 DOH 820-115 Glove and Other PPE Guidance for COVID-19 Vaccine Administration The purpose of this guidance document is to outline glove recommendations for providers administering the COVID-19 vaccine. Glove Use for Vaccine Administration Gloves are not recommended for most vaccination administration and are not required for the COVID-19 vaccine unless the person administering the vaccine is likely to come into contact with potentially infectious body fluids or has open lesions on their hands. If used improperly, gloves can increase the likelihood of spreading germs. If gloves are worn during vaccine administration: • They should be changed between patients along with performing proper hand hygiene. • Vinyl gloves are appropriate. • If nitrile gloves are a limited resource, prioritize/consider appropriate uses for nitrile gloves. • Gloves are single use and cannot be washed. • Improper aseptic technique or hand hygiene measures can increase the risk of infections in both the patient and the individual performing the vaccination. Other PPE Requirements • Vaccine providers should follow standard precautions and transmission-based precautions outlined by the Centers for Disease Control and Prevention. • A face mask and eye protection are required based on current community transmission. Healthcare personnel working facilities located in areas with moderate to substantial community transmission should wear a face mask and eye protection with every patient encounter. These do not need to be changed between patients unless they are soiled. An N95 or equivalent higher-level respirator is not generally required for vaccine administration unless indicated by transmission-based precautions. Hand Hygiene Implement infection control measures before patient arrival, upon arrival, throughout the visit, and until fully cleaned and disinfected.
    [Show full text]